- Conditions
- Lung Cancer
- Interventions
- Virtual Navigation System
- Diagnostic Test
- Lead sponsor
- Penn State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 889–912
of 11,349
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Neoplasms
- Interventions
- E7389
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 16
- States / cities
- Jonesboro, Arkansas • Deer Park, California • La Verne, California + 13 more
- Conditions
- Metastatic Solid Tumors
- Interventions
- SLV-324 intravenous (IV infusion)
- Drug
- Lead sponsor
- Solve Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 7
- States / cities
- Newport Beach, California • St Louis, Missouri • Cleveland, Ohio + 3 more
- Conditions
- Neoplasm Metastasis, Advanced Tumors, Metastatic Solid Tumors
- Interventions
- Ezabenlimab, BI 754111, BI 836880
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 211 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 11
- States / cities
- La Jolla, California • Fort Myers, Florida • St. Petersburg, Florida + 8 more
- Conditions
- Prostatic Neoplasms, Castration-Resistant, Neoplasms by Histologic Type, Neoplasms, Prostate, Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Neoplasms, Prostatic Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms, Neoplasms by Site, Prostatic Disease, Salivary Gland Cancer, Salivary Gland Tumor, Adenoid Cystic Carcinoma, Salivary Duct Carcinoma, Mucoepidermoid Carcinoma, Acinic Cell Tumor
- Interventions
- P-PSMA-101 CAR-T cells, Rimiducid
- Biological · Drug
- Lead sponsor
- Poseida Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 10
- States / cities
- Duarte, California • San Diego, California • San Francisco, California + 6 more
- Conditions
- Fibrodysplasia Ossificans Progressiva
- Interventions
- Palovarotene, Placebo
- Drug
- Lead sponsor
- Clementia Pharmaceuticals Inc.
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 2
- States / cities
- San Francisco, California • Philadelphia, Pennsylvania
- Conditions
- Clostridium Difficile Infection
- Interventions
- Placebo, CRS3123
- Other · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Breast Cancer, HER2-negative Breast Cancer, Germline BRCA1 Gene Mutation, Germline BRCA2 Gene Mutation, Deleterious PALB2 Gene Mutation
- Interventions
- Niraparib, Dostarlimab
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 8
- States / cities
- New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 3 more
- Conditions
- Advanced Solid Tumors
- Interventions
- Lapatinib and bortezomib
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Infections, Human Immunodeficiency Virus and Herpesviridae
- Interventions
- GSK1349572, Efavirenz
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Superficial Basal Cell Carcinoma
- Interventions
- PEP005
- Drug
- Lead sponsor
- Peplin
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 9
- States / cities
- Mesa, Arizona • Oceanside, California • San Diego, California + 6 more
- Conditions
- Healthy
- Interventions
- PF-06480605, Placebo
- Drug
- Lead sponsor
- Telavant, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Cirrhosis, Ascites, Hepatorenal Syndrome, Acute Kidney Injury
- Interventions
- OCE-205, Placebo
- Drug
- Lead sponsor
- Ocelot Bio, Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 18 more
- Conditions
- Gastroenteritis Escherichia Coli
- Interventions
- Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- delandistrogene moxeparvovec
- Genetic
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Industry
- Eligibility
- 3 Months to 7 Years · Male only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Peripheral T-cell Lymphoma
- Interventions
- brentuximab vedotin, cyclophosphamide, doxorubicin, prednisone
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Stanford, California • Aurora, Colorado + 25 more
- Conditions
- Tumors (Others), Viscera, Masses
- Interventions
- Percutaneous non-vascular access to anatomic structures
- Device
- Lead sponsor
- Cook Research Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Lung Cancer, SCLC
- Interventions
- Nivolumab, Plinabulin, Ipilimumab
- Drug
- Lead sponsor
- Salma Sabbour
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 8
- States / cities
- Duarte, California • Tampa, Florida • Chicago, Illinois + 5 more
- Conditions
- Non-Small Cell Lung Cancer, Leptomeningeal Metastases, Brain Metastases
- Interventions
- Tesevatinib
- Drug
- Lead sponsor
- Kadmon Corporation, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 7
- States / cities
- Beverly Hills, California • Newport Beach, California • Santa Monica, California + 4 more
- Conditions
- Coronavirus Disease (COVID-19)
- Interventions
- V591, Placebo
- Biological · Other
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 263 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 4
- States / cities
- Hollywood, Florida • Wichita, Kansas • Lexington, Kentucky + 1 more
- Conditions
- Presbyopia
- Interventions
- AGN-199201 ophthalmic solution, AGN-190584 ophthalmic solution, AGN-199201 Vehicle, AGN-190584 Vehicle
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 40 Years to 55 Years
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 25
- States / cities
- Arcadia, California • Artesia, California • Cypress, California + 19 more
- Conditions
- Pancreatic Cancer, Pancreatic Diseases, Pancreatitis, Pancreatic Cyst
- Interventions
- Blood Draw, Tumor Tissue Collection, Cyst Fluid
- Diagnostic Test
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2026
- U.S. locations
- 10
- States / cities
- Middletown, New Jersey • Montvale, New Jersey • Cold Spring Harbor, New York + 4 more
- Conditions
- Geographic Atrophy
- Interventions
- RO7303359
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 12
- States / cities
- Mountain View, California • Sacramento, California • Santa Maria, California + 9 more
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Multiple Myeloma
- Interventions
- CM-CS1 T-cell infusion
- Biological
- Lead sponsor
- Celyad Oncology SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts